The U.S. FDA has approved Celcuity’s drug for an advanced form of breast cancer, the regulator said on Tuesday, making it the company’s first product to gain market entry and sending its shares up seven per cent in afternoon trading.
The U.S. Food and Drug Administration’s approval was based on late-stage data showing the drug, gedatolisib, branded as Revtorpyk, when combined with Pfizer’s Ibrance and fulvestrant, reduced the risk of disease progression or death by 76 per cent compared with fulvestrant alone.
Get weekly health news
Revtorpyk is intended to treat patients with advanced breast cancer whose tumors have low levels of a protein called HER2 and no mutation in a gene called PIK3CA, and whose disease has worsened after hormone therapy and a CDK inhibitor, a type of therapy.
- PHAC finds no evidence of mystery brain disease in New Brunswick, says patients still need answers
- Beer recall hits 2 more Canadian products, bringing total to 31
- Alberta expanding use of AI tech that speeds up MRIs after successful pilot
- Stopping GLP-1 drugs could increase heart attack risk for some, study says
-
![]()
Health Matters: Pfizer to halt sales of certain hormone therapy -
![]()
CFL Fans Fight Cancer celebrates 20 years of making a difference and set record $100,000 fundraising goal -
![]()
Health-care workers dealing with more violent incidents -
![]()
The Quebec Health Institute signals early flu season as hospital ER room capacity surges
Patients receiving the combination remained progression-free for a median of 9.3 months, compared with 2.0 months for patients receiving fulvestrant alone.
Comments
Want to discuss? Please read our Commenting Policy first.